Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of Epstein Cj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Epstein Cj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Epstein Cj more than expected).
This network shows the impact of papers produced by Epstein Cj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Epstein Cj. The network helps show where Epstein Cj may publish in the future.
Co-authorship network of co-authors of Epstein Cj
This figure shows the co-authorship network connecting the top 25 collaborators of Epstein Cj.
A scholar is included among the top collaborators of Epstein Cj based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Epstein Cj. Epstein Cj is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
16 of 16 papers shown
1.
Cj, Epstein, et al.. (1996). Neuroprotective role of CuZn-superoxide dismutase in ischemic brain damage.. PubMed. 71. 271–280.22 indexed citations
2.
Cj, Epstein. (1995). Epilogue: toward the twenty-first century with Down syndrome--a personal view of how far we have come and of how far we can reasonably expect to go.. PubMed. 393. 241–6.13 indexed citations
3.
Holtzman, DM, et al.. (1995). Preliminary characterization of the central nervous system in partial trisomy 16 mice.. PubMed. 393. 227–40.19 indexed citations
4.
Kondo, T., S. IMAIZUMI, I. Kato, et al.. (1994). [Effect of free radicals on the permeability of the blood brain barrier--using in vitro blood brain barrier model of human-SOD transgenic mouse].. PubMed. 46(12). 1155–61.4 indexed citations
5.
Cj, Epstein. (1993). The conceptual bases for the phenotypic mapping of conditions resulting from aneuploidy.. PubMed. 384. 1–18.10 indexed citations
6.
Holtzman, DM, et al.. (1992). Preliminary characterization of long-term reaggregating cultures of trisomy 16 central nervous system.. PubMed. 379. 259–70.1 indexed citations
Cj, Epstein, et al.. (1987). Abnormalities in the interferon response and immune systems in Down syndrome: studies in human trisomy 21 and mouse trisomy 16.. PubMed. 246. 191–208.11 indexed citations
Cj, Epstein. (1967). Social aspects of medical genetics.. PubMed. 36(4). 224–7.1 indexed citations
16.
Cj, Epstein, et al.. (1965). Werner's syndrome; caricature of aging. A genetic model for the study of degenerative diseases.. PubMed. 78. 73–81.14 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.